Camptothecin

Camptothecin

SCHEMBL1980674

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1.[N-]=[N+]=[N-]

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP1 P11387 18/20 0.93
ALDH1A1 P00352 4/20 0.93
MEN1 O00255 4/20 0.93
KMT2A Q03164 4/20 0.93
SMN1; SMN2 Q16637 4/20 0.93
KDM4E B2RXH2 3/20 0.93
GLA P06280 3/20 0.93
TP53 P04637 2/20 0.93
HPGD P15428 2/20 0.93
CYP3A4 P08684 2/20 0.93
HBB P68871 2/20 0.93
STAT6 P42226 1/20 0.93
CHEK1 O14757 1/20 0.93
HDAC3 O15379 1/20 0.93
ABCC4 O15439 1/20 0.93
GMNN O75496 1/20 0.93
LMNA P02545 1/20 0.93
CYP1A2 P05177 1/20 0.93
HNRNPA1 P09651 1/20 0.93
GAA P10253 1/20 0.93

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Camptothecin SCHEMBL4304557 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL28057307 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL29360250 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL29369924 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL788063 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL6038 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL2298909 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL29351099 0.96 TOP1 (1.00) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL548833 0.95 TOP1 (0.98) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2
Camptothecin SCHEMBL17112859 0.95 TOP1 (0.98) TOP1ALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197810-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC. 2024-06-20 US disclosed
US-11819531-B2 Multifunctional zwitterionic polymer conjugates KODIAK SCIENCES INC. (US) 2023-11-21 US disclosed
EP-3659591-B1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC (US) 2023-10-25 EP disclosed
US-20230277616-A9 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC. 2023-09-07 US disclosed
US-11213593-B2 Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates NORTHWESTERN UNIVERSITY (US) 2022-01-04 US disclosed
CN-107596380-B Polyethylene glycol-polycarbonate-based reduction-sensitive camptothecin prodrug and preparation method and application thereof 河南师范大学 2020-09-11 CN disclosed
EP-3659591-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES Kodiak Sciences Inc. (US) 2020-06-03 EP disclosed
EP-3254678-B1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC (US) 2020-02-19 EP disclosed
US-20180344873-A1 THE SEQUENCE-SPECIFIC CELLULAR UPTAKE OF SPHERICAL NUCLEIC ACID NANOPARTICLE NORTHWESTERN UNIVERSITY 2018-12-06 US disclosed
EP-3220895-A2 THE SEQUENCE-SPECIFIC CELLULAR UPTAKE OF SPHERICAL NUCLEIC ACID NANOPARTICLE CONJUGATES Northwestern University (US) 2017-09-27 EP disclosed
US-20170007710-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES KODIAK SCIENCES INC. 2017-01-12 US disclosed
US-20160287715-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES KODIAK SCIENCES INC (US) 2016-10-06 US disclosed
WO-2016081911-A2 THE SEQUENCE-SPECIFIC CELLULAR UPTAKE OF SPHERICAL NUCLEIC ACID NANOPARTICLE CONJUGATES NORTHWESTERN UNIVERSITY (US) 2016-05-26 WO disclosed
US-20150004128-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES OLIGASIS, LLC (US) 2015-01-01 US disclosed
US-8765432-B2 Targeted drug phosphorylcholine polymer conjugates OLIGASIS, LLC (US) 2014-07-01 US disclosed
US-20130045522-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES OLIGASIS (US) 2013-02-21 US disclosed
US-20130034517-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES OLIGASIS (US) 2013-02-07 US disclosed
EP-2512462-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES Oligasis (US) 2012-10-24 EP disclosed
WO-2011075185-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES OLIGASIS (US) 2011-06-23 WO disclosed
WO-2011075736-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES OLIGASIS (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277616-A9 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES PHOSPHO1, MSN, ZW10 TOP1 1340/4885ALDH1A1 4195/4885MEN1 1142/4885
US-20160287715-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES PHOSPHO1, MSN, ZW10 TOP1 1340/4885ALDH1A1 4195/4885MEN1 1142/4885
US-20130034517-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES PHOSPHO1, EPHA2, PCTP TOP1 895/4885ALDH1A1 4156/4885MEN1 2351/4885
US-20170007710-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES PHOSPHO1, EPHA2, PCTP TOP1 895/4885ALDH1A1 4156/4885MEN1 2351/4885
US-20150004128-A1 TARGETED DRUG PHOSPHORYLCHOLINE POLYMER CONJUGATES PHOSPHO1, EPHA2, PCTP TOP1 895/4885ALDH1A1 4156/4885MEN1 2351/4885
US-20240197810-A1 MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES PHOSPHO1, MSN, ZW10 TOP1 1340/4885ALDH1A1 4195/4885MEN1 1142/4885
US-11819531-B2 Multifunctional zwitterionic polymer conjugates PHOSPHO1, MSN, ZW10 TOP1 1340/4885ALDH1A1 4195/4885MEN1 1142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.